-
The FDA will review Dyne’s application for Accelerated Approval of z-rostudirsen for skipping exon 51
CureDuchenne was an early funder of Dyne Therapeutics, and we are pleased to share that the FDA has accepted the BLA (Biologics License Application) for z-rostudirsen for individuals with Duchenne amenable to skipping exon 51. This submission is for Accelerated Approval based on dystrophin as a surrogate endpoint, and the FDA has granted the application…
-
I wanted my oldest son with DMD to go to college more than he did
As the summer flies by, my thoughts turn to going back to school — reluctantly. As a mother of many, the end of summer is nothing new. I have seven children with my husband, Jason: Lexi, 25; Max, 20; Chance, 19; Rowen, 17; Charlie, 15; Mary, 11; and Callie, 4. Max, Rowen, and Charlie have Duchenne…








